{
    "relation": [
        [
            "",
            "Rotarix Group",
            "Placebo Group"
        ],
        [
            "Description",
            "Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix\u2122 HepB Hib and Polio Sabin\u2122 vaccines.",
            "Subjects received 3 doses of placebo co-administered with routine Tritanrix\u2122 HepB Hib and Polio Sabin\u2122 vaccines."
        ]
    ],
    "pageTitle": "A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00263666?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990112.50/warc/CC-MAIN-20150728002310-00323-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 851348534,
    "recordOffset": 851332596,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups In case of discrepancy between the HIV results (DNA PCR positive, viral load negative), performed at the Screening Visit (one week prior to first vaccination) the infants were not enrolled in the study. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: Rotarix Biological: Placebo Biological: TritanrixTM-HB+Hib Biological: SabinPolioTM vaccine Interventions: Rotavirus Gastroenteritis Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design: Interventional",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Rotarix Group \u00a0 \u00a0 Placebo Group \u00a0 STARTED \u00a0 \u00a0 50 \u00a0 \u00a0 50 \u00a0 COMPLETED \u00a0 \u00a0 43 \u00a0 \u00a0 39 \u00a0 NOT COMPLETED \u00a0 \u00a0 7 \u00a0 \u00a0 11 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 6 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 8 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}